BACKGROUND: High-dose trivalent influenza vaccine was developed to improve antibody
responses to influenza vaccine in the elderly and hence potentially impact favorably on …

Background As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated
influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 …

ABSTRACT A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for
adults≥ 65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has …

Background Enhanced influenza vaccines may improve protection for older adults, but
comparative immunogenicity data are limited. Our objective was to examine immune …

Background A randomized trial demonstrated that a high-dose inactivated influenza vaccine
(IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against …

Background: Influenza is responsible for a significant disease burden annually, especially in
older adults. This study reviews the relative vaccine efficacy or effectiveness (rVE) of high …

Introduction Older adults are prioritized for influenza vaccination but also have lowered
antibody responses to the vaccine. Higher-doses of influenza antigen may increase immune …

This updated systematic review and meta-analysis of randomized and observational studies
published up to April 2023 assessed the relative performance of high-dose inactivated …

Background. Influenza is a significant cause of morbidity and mortality in older adults. High-
dose (HD) trivalent inactivated vaccine has increased immunogenicity in older adults …

Background Influenza-associated morbidity and mortality has not decreased in the last
decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza …